Clinical trials: Multisystem Inflammatory Syndrome-Children

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

• No Longer Available
• Age: 2 months to 17 years
• Expanded access
• Injection or infusion

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.

Trial name

NCT04456439

Testing

Remestemcel-L, Hydrocortisone, Diphenhydramine

Sponsor

Mesoblast International Sàrl